Blueprint Medicines Corp BPMC.OQ BPMC.O is expected to show a rise in quarterly revenue when it reports results on May 1 for the period ending March 31 2025
The Cambridge Massachusetts-based company is expected to report a 61.9% increase in revenue to $155.607 million from $96.12 million a year ago, according to the mean estimate from 19 analysts, based on LSEG data.
LSEG's mean analyst estimate for Blueprint Medicines Corp is for a loss of 52 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 0.7% in the last three months.
Wall Street's median 12-month price target for Blueprint Medicines Corp is $130.00, above its last closing price of $88.51.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.68 | -0.70 | -0.79 | Missed | -12.3 |
Sep. 30 2024 | -0.92 | -0.97 | -0.89 | Beat | 7.9 |
Jun. 30 2024 | -1.30 | -1.29 | -0.80 | Beat | 38 |
Mar. 31 2024 | -1.65 | -1.66 | -1.32 | Beat | 20.6 |
Dec. 31 2023 | -2.06 | -2.04 | -1.82 | Beat | 10.8 |
Sep. 30 2023 | -2.33 | -2.37 | -2.20 | Beat | 7.1 |
Jun. 30 2023 | -2.54 | -2.54 | -2.19 | Beat | 13.8 |
Mar. 31 2023 | -2.69 | -2.67 | -2.15 | Beat | 19.5 |
This summary was machine generated April 29 at 13:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。